Earlier this year, Novartis spent $8.7 billion acquiring AveXis to land AVXS-101, and depending on data, Novartis plans to file for FDA approval of AVXS-101 before the end of 2018. If AVXS-101 ... is ...
by via Azon , Big Sales , July 2018 | Automatic Website Traffic RSS https://ift.tt/2J16Hwj July 07, 2018 at 03:10PM
No comments:
Post a Comment